Eam Investors, LLC Arcus Biosciences, Inc. Transaction History

Eam Investors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$28.92 - $41.83 $2.2 Million - $3.19 Million	-76,163 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$31.38 - $48.47 $2.39 Million - $3.69 Million	76,163 New	76,163 $3.08 Million
Q3 2020 Nov 13, 2020	SELL	$17.14 - $25.47 $1.12 Million - $1.67 Million	-65,606 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $916,515 - $2.4 Million	65,606 New	65,606 $1.62 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.